What is TRAVATAN?
TRAVATAN is a clear eye drop solution containing the active substance travoprost.
What is TRAVATAN used for?
TRAVATAN is used to reduce intraocular pressure (inside the eye). It is used in patients with open-angle glaucoma (a disease in which the pressure in the eye rises because fluid cannot flow out of the eye) and in patients with ocular hypertension (eye pressure above normal).
The medicine can only be obtained with a prescription.
How is TRAVATAN used?
The dosage is one drop of TRAVATAN in the affected eye (s) once a day, preferably in the evening. The use of TRAVATAN is not recommended in patients under 18 years of age.
How does TRAVATAN work?
When intraocular pressure increases, it causes damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve (nerve responsible for sending signals from the eye to the brain), causing severe vision loss. and even blindness. By lowering blood pressure, TRAVATAN reduces the risk of injury. The active substance in TRAVATAN, travoprost, is a prostaglandin analogue (an artificial copy of a natural substance, prostaglandin).
In the eye, prostaglandin increases the drainage of the aqueous humor (transparent liquid present inside the eye) towards the outside. TRAVATAN acts in the same way, increasing the outflow of the aqueous humor, thus reducing the pressure inside the eye. "eye.
How has TRAVATAN been studied?
TRAVATAN has been studied in 1,989 patients in three main studies, lasting 6-12 months. All three studies compared travoprost with timolol, the medicine commonly used in the treatment of glaucoma. One of the three studies has It also included a comparison with latanoprost (another prostagladin analog used for the treatment of glaucoma). The main measure of effectiveness was the reduction of intraocular pressure. Another study compared the efficacy of TRAVATAN as an adjunct therapy in the treatment of patients already using timolol (427 patients, duration of 6 months).
What benefit has TRAVATAN shown during the studies?
TRAVATAN was at least as effective as timolol and as effective as latanoprost in reducing intraocular pressure. Combined treatment with TRAVATAN and timolol resulted in a "further decrease in intraocular pressure in patients not controlled on timolol alone.
What is the risk associated with TRAVATAN?
The most common side effects seen with the use of TRAVATAN (seen in more than 1 in 10 patients) are ocular hyperaemia (increased blood flow to the eye, which causes irritation and redness of the eye) and change in eyelashes, including "increase in the length, thickness or number of lashes. For the full list of side effects reported with TRAVATAN, see the Package Leaflet.
TRAVATAN must not be used in people who are hypersensitive (allergic) to travoprost or any of the other substances. TRAVATAN contains benzalkonium chloride, which can make soft contact lenses dull. Therefore, people who wear soft contact lenses need to be especially careful.
Why has TRAVATAN been approved?
The Committee for Medicinal Products for Human Use (CHMP) decided that TRAVATAN's benefits are greater than its risks for the treatment of increased intraocular pressure in patients with open-angle glaucoma or ocular hypertension and therefore recommended that it be licensed. upon placing on the market.
Other information about TRAVATAN
On November 27, 2001, the European Commission granted Alcon Laboratories (UK) Limited a "Marketing Authorization" for TRAVATAN, valid throughout the European Union.
The marketing authorization was renewed on November 27, 2006.
For the full version of the TRAVATAN EPAR click here.
Last update of this summary: 02-2007.
The information on TRAVATAN - travoprost published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
